American Association for Cancer Research (AACR) Annual Meeting 2021 April 10, 2021 Supporting Materials Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, alone and in combination with anti-PD1 antibody in patients (pts) with HER2-expressing advanced solid tumors 2.5 MB Targeting HERS2 with Immune-Stimulating Antibody Conjugates (ISACS) 1.6 MB
Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, alone and in combination with anti-PD1 antibody in patients (pts) with HER2-expressing advanced solid tumors 2.5 MB
